Expertise in
7
conditions

Dr. Vivek Subbiah

Oncology
Office
335 24th Ave N Ste 200, 
Nashville, TN 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Expertise in
7
conditions
Office
335 24th Ave N Ste 200, 
Nashville, TN 

Overview

Vivek Subbiah is an Oncologist practicing medicine in Nashville, Tennessee.

Dr. Subbiah is highly rated in 7 conditions, according to our data. His clinical expertise encompasses Adult Soft Tissue Sarcoma, PIK3CA-Related Overgrowth Spectrum, Ewing Sarcoma, and Desmoplastic Small Round Cell Tumor.

He is actively involved in clinical research, co-authoring 582 peer reviewed articles and participating in 28 clinical trials.

Specialties

Oncology

Licenses

Internal Medicine in CA

Hospital Affiliations

Tristar Centennial Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
US Health and Life
  • EPO
  • PPO
View 5 Less Insurance Carriers -

Locations

Office
335 24th Ave N Ste 200, Nashville, TN 37203

Additional Areas of Focus

Dr. Subbiah has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)
Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

28 Clinical Trials

An Open-Label, Multicenter, First-in-Human, Phase 1 Dose-Escalation and Multicohort Expansion Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
An Open-Label, Multicenter, First-in-Human, Phase 1 Dose-Escalation and Multicohort Expansion Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
Enrollment Status: Recruiting
Publish Date: May 22, 2026
Intervention Type: Drug
Study Drugs: INBRX-109 Tetravalent DR5 Agonist Antibody, Carboplatin, Cisplatin, Pemetrexed, 5-Fluorouracil, Irinotecan
Study Phase: Phase 1
A Phase II Basket Trial of Glutaminase Inhibitor (BEGIN) Telaglenastat (CB-839) HCL in Patients With NF1 Aberrations, NF1 Mutant Malignant Peripheral Nerve Sheath Tumors (MPNST), KEAP1/NRF2 and LKB1 Aberrant Tumors
A Phase II Basket Trial of Glutaminase Inhibitor (BEGIN) Telaglenastat (CB-839) HCL in Patients With NF1 Aberrations, NF1 Mutant Malignant Peripheral Nerve Sheath Tumors (MPNST), KEAP1/NRF2 and LKB1 Aberrant Tumors
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Procedure, Drug, Other
Study Drug: Telaglenastat Hydrochloride
Study Phase: Phase 2
An Open-label, Single-Center, Phase 1b/2 Study to Evaluate the Safety of Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Malignancies After Progression on PD-1 or PD-L1 Targeted Antibodies
An Open-label, Single-Center, Phase 1b/2 Study to Evaluate the Safety of Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Malignancies After Progression on PD-1 or PD-L1 Targeted Antibodies
Enrollment Status: Terminated
Publish Date: April 30, 2026
Intervention Type: Drug, Biological, Radiation
Study Drugs: Atezolizumab, Avelumab, Durvalumab, Nivolumab, Pembrolizumab, Plinabulin
Study Phase: Phase 1/Phase 2
A Phase 1/2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001)
A Phase 1/2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001)
Enrollment Status: Active_not_recruiting
Publish Date: April 16, 2026
Intervention Type: Drug
Study Drug: Selpercatinib
Study Phase: Phase 1/Phase 2
A Phase 1/2 Trial of a Novel Therapeutic Vaccine (EO2401) in Combination With Immune Check Point Blockade, for Treatment of Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma
A Phase 1/2 Trial of a Novel Therapeutic Vaccine (EO2401) in Combination With Immune Check Point Blockade, for Treatment of Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma
Enrollment Status: Terminated
Publish Date: January 30, 2026
Intervention Type: Biological
Study Drugs: EO2041, Nivolumab
Study Phase: Phase 1/Phase 2
A Phase 1a/1b Study of LY3405105 Administered to Patients With Advanced Solid Tumors
A Phase 1a/1b Study of LY3405105 Administered to Patients With Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: November 04, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1 Trial of Vandetanib (a Multi-Kinase Inhibitor of EGFR, VEGFR, and RET Inhibitor) in Combination With Everolimus (an mTOR Inhibitor) in Advanced Cancer
A Phase 1 Trial of Vandetanib (a Multi-Kinase Inhibitor of EGFR, VEGFR, and RET Inhibitor) in Combination With Everolimus (an mTOR Inhibitor) in Advanced Cancer
Enrollment Status: Completed
Publish Date: October 27, 2025
Intervention Type: Drug, Other
Study Phase: Phase 1
An Open-Label Phase 1b Study of the Safety, Tolerability, and Preliminary Antitumor Activity of INCB059872 in Participants With Relapsed or Refractory Ewing Sarcoma
An Open-Label Phase 1b Study of the Safety, Tolerability, and Preliminary Antitumor Activity of INCB059872 in Participants With Relapsed or Refractory Ewing Sarcoma
Enrollment Status: Terminated
Publish Date: October 21, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
Enrollment Status: Completed
Publish Date: August 14, 2025
Intervention Type: Drug
Study Drugs: INCAGN01876, Nivolumab, Ipilimumab
Study Phase: Phase 1/Phase 2
A Phase I/II, Multicenter, Open-label Study of MAK683 in Adult Patients With Advanced Malignancies
A Phase I/II, Multicenter, Open-label Study of MAK683 in Adult Patients With Advanced Malignancies
Enrollment Status: Terminated
Publish Date: August 11, 2025
Intervention Type: Drug
Study Drug: MAK683
Study Phase: Phase 1
View 9 Less Clinical Trials

582 Total Publications

Tumor-Agnostic Therapies: Translating Scientific Breakthroughs Into Global Implementation.
Tumor-Agnostic Therapies: Translating Scientific Breakthroughs Into Global Implementation.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 01, 2026
Similar Doctors
Expertise in
43
conditions
Expertise in
43
conditions
Referral may be required

Tennessee Oncology, PLLC-#412 25th Ave

250 25th Ave N, Ste 412, 
Nashville, TN 
 (1.2 miles away)
615-986-7600
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Ian Flinn is an Oncologist practicing medicine in Nashville, Tennessee. Dr. Flinn is highly rated in 43 conditions, according to our data. His clinical expertise encompasses Small Lymphocytic Lymphoma (SLL), Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Flinn is board certified in The American Board Of Internal Medicine - Hematology. Dr. Flinn is currently accepting new patients.

Expertise in
24
conditions
Expertise in
24
conditions
Referral may be required

SCRI Oncology Partners

335 24th Ave N, Ste 200, 
Nashville, TN 
 (0.1 miles away)
615-329-7640
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Erika Hamilton, MD, is an independent medical oncologist and hematologist at Ascension Saint Thomas in Nashville, Tennessee. Dr. Hamilton diagnoses and treats adults with cancer and focuses on managing care during and after chemotherapy, radiation therapy and surgery. Every appointment with Dr. Hamilton starts with a conversation. She takes the time to answer all your questions — big and small. Dr. Hamilton is highly rated in 24 conditions, according to our data. Her clinical expertise encompasses Breast Cancer, HER2 Negative Breast Cancer, Ovarian Cancer, and HER-2 Positive Breast Cancer. Dr. Hamilton is board certified in The American Board Of Internal Medicine - Medical Oncology. Dr. Hamilton is currently accepting new patients.

Expertise in
41
conditions
Expertise in
41
conditions
Referral may be required

Tennessee Oncology, PLLC-#412 25th Ave

250 25th Ave N, Ste 412, 
Nashville, TN 
 (1.2 miles away)
615-986-7600
Languages Spoken:
English, French, Russian, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Jesus Berdeja is an Oncologist practicing medicine in Nashville, Tennessee. Dr. Berdeja is highly rated in 41 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Smoldering Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Berdeja is board certified in The American Board Of Internal Medicine - Hematology. Dr. Berdeja is currently accepting new patients.

Frequently Asked Questions about Dr. Vivek Subbiah

How do I make an appointment with Dr. Vivek Subbiah?

You can book an appointment with Dr. Vivek Subbiah by calling their office at 615-398-9890. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Vivek Subbiah a top-rated expert for Adult Soft Tissue Sarcoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Vivek Subbiah is classified as an Distinguished expert for Adult Soft Tissue Sarcoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Vivek Subbiah specialize in?

While Dr. Vivek Subbiah is a Oncology, they have specific expertise in Adult Soft Tissue Sarcoma, PIK3CA-Related Overgrowth Spectrum, and Ewing Sarcoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Vivek Subbiah participate in research or clinical trials?

Yes. Dr. Vivek Subbiah has published 582 articles and abstracts on conditions like Adult Soft Tissue Sarcoma. You can view a list of Dr. Vivek Subbiah's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Vivek Subbiah accept my insurance?

Dr. Vivek Subbiah accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 615-398-9890 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Subbiah's expertise for a condition
ConditionClose
    View All 22 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile